Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients.:Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y. Eur Urol 57 (2) :317-326, 2010.
Prognostic factors influencing survival after nephroureterectomy for transitional cell carcinoma of the upper urinary tract.:Kobayashi Y, Saika T, Manabe D, Nasu Y, Kumon H. Acta Med Okayama 64 (1) :27-31, 2010.
Epidemiology of Chlamydophila caviae-like Chlamydia isolated from urethra and uterine cervix.:Murao W, Wada K, Matsumoto A, Fujiwara M, Fukushi H, Kishimoto T, Monden K, Kariyama R, Kumon H. Acta Med Okayama 64 (1) :1-9, 2010.
In vitro drug susceptibility of mycobacterium bovis BCG connaught and Tokyo strains.:Shimizu T,Yasumoto K,Tatano Y,Tomioka H,Sato K,Sano C,Kumon H,Monden K. Journal of Infection 60 (3) :248-251, 2010.
The future of urodynamics: Non-invasive ultrasound videourodynamics.:Ozawa H,Igarashi T,Uematsu K,Watanabe T,Kumon H. Int J Urol 17 (3) :241-249, 2010.
Robot-assisted laparoscopic radical prostatectomy in the Asian population: Modified port configuration and ultradissection.:Jeong W,Araki M,Park SY,Lee YH,Kumon H,Hong SJ,Rha KH. Int J Urol 17 (3) :297-300, 2010.
Cell-penetrating d-isomer peptides of p53 C-terminus: long-term inhibitory effect on the growth of bladder cancer.:Araki D,Takayama K,Inoue M,Watanabe T,Kumon H,Futaki S,Matsui H,Tomizawa K. Urology 75 (4) :813-819, 2010.
Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3.:Tanimoto R,Sakaguchi M,Abarzua F,Kataoka K,Kurose K,Murata H,Nasu Y,Kumon H,Huh NH. Int J Cancer 126 (7) :1562-1569, 2010.
Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus(OBP-301)and IL-2 in a mouse model of renal cell carcinoma.:Huang P, Kaku H, Chen J, Kashiwakura Y, Saika T, Nasu Y, Urata Y, Fujiwara T, Watanabe M, Kumon H. Cancer Gene Ther 17 (7) :484-491, 2010.
A randomized phase II traial of personalized peptide vaccine plus low dose estramustin phosphate(EMP)versus standard dose EMP in patients with castration resistant prostate cancer.:Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. Cancer Immunol Immunother 59 (7) :1001-1009, 2010.
Three novel NY-ESO-1 epitopes bound to DRB1 0803,DQB1 0401 and DRB1 0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients.:Mizote Y,Taniguchi T,Tanaka K,Isobe M,Wada H,Saika T,Kita S,Koide Y,Uenaka A,Nakayama E. Vaccine 28 (32) :5338-5346, 2010.
Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.:Saika T,Tsushima T,Nasu Y,Miyaji Y,Saegusa M,Takeda K,Kumon H. World J Urol 28 (4) :413-418, 2010.
5αDH-DOC(5α-dihydro-deoxycorticosterone)activates androgen receptor in castration-resistant prostate cancer.:Uemura M,Honma S,Chung S,Takata R,Furihata M,Nishimura K,Nonomura N,Nasu Y,Miki T,Shuin T,Fujioka T,Okuyama A,Nakamura Y,Nakagawa H. Cancer Sci 101 (8) :1897-1904, 2010.
Hepatocyte growth factor activator inhibitors(HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.:Nakamura K,Abarzua F,Hongo A,Kodama J,Nasu Y,Kumon H,Hiramatsu Y. Int J Oncol 37 (3) :605-614, 2010.
Bladder cancer working group report.:Kakehi Y,Hirao Y,Kim W-J,Ozono S,Masumori N,Miyanaga N,Nasu Y,Yokomizo A. Jpn J Clin Oncol 40 (Suppl1) :57-64, 2010.
Indications for ureteropyeloscopy based on radiographic findings and urine cytology in detection of upper urinary tract carcinoma.:Takao A,Saika T,Uehara S,Monden K,Abarzua F,Nasu Y,Kumon H,Okayama Urological Research Group. Jpn J Clin Oncol 40 (11) :1087-1091, 2010.
Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development.:Zhang K,Watanabe M,Kashiwakura Y,Li S-A,Edamura K,Huang P,Yamaguchi K,Nasu Y,Kobayashi Y,Sakaguchi M,Ochiai K,Yamada H,Takei K,Ueki H,Huh N-H,Li M,Kaku H,Na Y,Kumon H. Int J Oncol 37 (6) :1495-1501, 2010.
Does greenlight HPS™ laser photoselective vaporization prostattectomy affect sexual function?:Spaliviero M,Strom KH,Gu X,Araki M,Culkin DJ,Wong C. J Endourol 24 (12) :2051-2057, 2010.
著書
The role of biofilm infection in urogenital infections.:Tenke P, Koves B, Uehara S, Kumon H, Hultgren S.J, Hung C(editors:Naber K.G, Scaeffer A.J, Heyns C.F, Matsumoto T, Shoskes D.A, Johansen T.E.B) Urogenital Infections(Grafos, Spain) :57-68, 2010.